Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin plus radiotherapy in elderly esophageal cancer
ChiCTR-OIC-17011436Phase 2Not yet recruiting
- Sponsor
- Affiliated Huai'an Hospital of Xuzhou Medical University
- Start
- May 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lobaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Huai'an Hospital of Xuzhou Medical University. Primary endpoint: Progression-free survival (PFS). Planned start May 2017; status: not yet recruiting.
02
Drugs
lobaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-OIC-17011436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011436.